Claims for Patent: 5,601,827

Summary for Patent: 5,601,827

Title:	Diphtheria toxin vaccines
Abstract:	A DNA encoding an immunologically cross-reactive form of diphtheria toxin Fragment A, wherein the codons corresponding to Val-147 and Glu-148 of naturally-occurring diphtheria toxin are deleted from the DNA.
Inventor(s):	Collier; R. John (Wellesley Hills, MA), Killeen; Kevin (Milton, MA), Mekalanos; John (Cambridge, MA)
Assignee:	President and Fellows of Harvard College (Cambridge, MA)
Application Number:	08/447,413
Patent Claims:	1. A DNA encoding an immunologically cross-reactive form of diphtheria toxin Fragment A, wherein the codons corresponding to Val-147 and Glu-148 of naturally-occurring diphtheria toxin (FIG. 1; SEQ ID NO:1) are absent from said DNA. 2. The DNA of claim 1, wherein said DNA further comprises a nucleic acid sequence encoding part or all of diphtheria toxin Fragment B. 3. The DNA of claim 1, wherein the codon corresponding to Glu-142 (FIG. 1; SEQ ID NO:1) is absent or is altered to encode an amino acid other than Glu. 4. The DNA of claim 3, wherein all of the codons from Glu-142 to Glu-148 (FIG. 1; SEQ ID NO:1) are absent. 5. The DNA of claim 1, wherein a codon corresponding to a third amino acid residue of said naturally occurring toxin is deleted or is altered to encode an amino acid residue different from said third amino acid residue of said naturally occurring toxin, the presence of said third amino acid residue of said naturally occurring toxin being essential for the full toxic activity of said naturally occurring toxin, said third amino acid residue being selected from the group consisting of His-21, Glu-22, Lys-39, Gly-52, Gly-79, Gly-128, Glu-142, Gly-143, Ser-144, Ser-145, Ser-146, Ala-158, Glu-162, Glu-349, Asp-352, and Ile-364 (FIG. 1; SEQ ID NO:1). 6. The DNA of claim 1, wherein said DNA includes a codon encoding Tyr-149 of naturally occurring diphtheria toxin. 7. A cell comprising the DNA of claim 1. 8. The cell of claim 7, wherein said cell is a B. subtilis, Bacillus Calmette-Guerin (BCG), Salmonella sp., Vibrio cholerae, Listeriae, Yersiniae, Streptococci, Corynebacterium diphtheriae, or an E. coli cell. 9. A vaccine comprising a prokaryotic cell containing the DNA of claim 5. 10. A vaccine comprising the cell of claim 7, wherein said cell is a prokaryote. 11. A method of using the DNA of claim 1 to prepare an immunologically cross-reactive form of diphtheria toxin Fragment A, wherein Val-147 and Glu-148 of naturally-occurring diphtheria toxin are absent, which method comprises culturing a cell comprising said DNA under conditions permitting the expression of said DNA. 12. A method of using the DNA of claim 1 in a vaccine, which method comprises culturing a prokaryotic cell comprising said DNA under conditions permitting proliferation of said cell, wherein said cell is suitable for introduction into an animal as a live-cell vaccine. 13. A method for immunizing a mammal against diphtheria, which method comprises introducing an immunizing amount of a vaccine made by the method of claim 12. 14. The method of claim 13, wherein said mammal is a human. 15. A method for immunizing a mammal against diphtheria, which method comprises introducing an immunizing amount of the vaccine of claim 10 into said mammal. 16. A DNA encoding a fusion polypeptide, wherein the DNA of claim 1 is fused in frame to a DNA encoding a second polypeptide. 17. A cell comprising the DNA of claim 16. 18. A vaccine comprising a prokaryotic cell comprising the DNA of claim 16. 19. A method of immunizing a human patient against diphtheria toxin comprising administering to a patient an immunogenically effective amount of the vaccine of claim 18.

Details for Patent 5,601,827

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2014-02-11